ID   OTUD5_HUMAN             Reviewed;         571 AA.
AC   Q96G74; B4DGG7; G5E9D7; Q4KMN9; Q8N6T5; Q9H650; Q9H9U0; Q9NT65;
DT   20-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   12-APR-2017, entry version 126.
DE   RecName: Full=OTU domain-containing protein 5;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme A;
DE            Short=DUBA;
GN   Name=OTUD5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 176-571 (ISOFORM 5), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 253-571 (ISOFORM 1).
RC   TISSUE=Brain, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Kidney, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 140-571 (ISOFORM 5).
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   FUNCTION, TISSUE SPECIFICITY, INTERACTION WITH TRAF3, AND MUTAGENESIS
RP   OF CYS-224; LEU-542 AND SER-549.
RX   PubMed=17991829; DOI=10.1126/science.1145918;
RA   Kayagaki N., Phung Q., Chan S., Chaudhari R., Quan C., O'Rourke K.M.,
RA   Eby M., Pietras E., Cheng G., Bazan J.F., Zhang Z., Arnott D.,
RA   Dixit V.M.;
RT   "DUBA: a deubiquitinase that regulates type I interferon production.";
RL   Science 318:1628-1632(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165; SER-177 AND
RP   SER-452, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165 AND SER-177, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   FUNCTION.
RX   PubMed=23827681; DOI=10.1016/j.cell.2013.05.046;
RA   Mevissen T.E., Hospenthal M.K., Geurink P.P., Elliott P.R., Akutsu M.,
RA   Arnaudo N., Ekkebus R., Kulathu Y., Wauer T., El Oualid F.,
RA   Freund S.M., Ovaa H., Komander D.;
RT   "OTU deubiquitinases reveal mechanisms of linkage specificity and
RT   enable ubiquitin chain restriction analysis.";
RL   Cell 154:169-184(2013).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-165 AND SER-177,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 172-339.
RG   Structural genomics consortium (SGC);
RT   "The catalytic domain of human OTUD5.";
RL   Submitted (DEC-2010) to the PDB data bank.
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) OF 172-351 IN COMPLEX WITH
RP   UBIQUITIN, CATALYTIC ACTIVITY, FUNCTION, INDUCTION, PHOSPHORYLATION AT
RP   SER-64; SER-165; TYR-175; SER-177 AND THR-507, MUTAGENESIS OF SER-177
RP   AND CYS-224, ACTIVE SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22245969; DOI=10.1038/nsmb.2206;
RA   Huang O.W., Ma X., Yin J., Flinders J., Maurer T., Kayagaki N.,
RA   Phung Q., Bosanac I., Arnott D., Dixit V.M., Hymowitz S.G.,
RA   Starovasnik M.A., Cochran A.G.;
RT   "Phosphorylation-dependent activity of the deubiquitinase DUBA.";
RL   Nat. Struct. Mol. Biol. 19:171-175(2012).
CC   -!- FUNCTION: Deubiquitinating enzyme that functions as negative
CC       regulator of the innate immune system. Acts via TRAF3
CC       deubiquitination and subsequent suppression of type I interferon
CC       (IFN) production. Has peptidase activity towards 'Lys-48'- and
CC       'Lys-63'-linked polyubiquitin chains. Can also cleave 'Lys-11'-
CC       linked ubiquitin chains (in vitro). {ECO:0000269|PubMed:17991829,
CC       ECO:0000269|PubMed:22245969, ECO:0000269|PubMed:23827681}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC       {ECO:0000269|PubMed:22245969}.
CC   -!- ENZYME REGULATION: Inhibited by N-ethyl-maleimide (NEM).
CC   -!- SUBUNIT: Interacts with TRAF3. {ECO:0000269|PubMed:17991829,
CC       ECO:0000269|PubMed:22245969}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q96G74-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96G74-2; Sequence=VSP_023195, VSP_023192;
CC         Note=No experimental confirmation available. Dubious isoform
CC         produced through aberrant splice sites.;
CC       Name=3;
CC         IsoId=Q96G74-3; Sequence=VSP_023192, VSP_023193, VSP_023194;
CC         Note=No experimental confirmation available. Dubious isoform
CC         produced through aberrant splice sites.;
CC       Name=4;
CC         IsoId=Q96G74-4; Sequence=VSP_045185, VSP_023192;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q96G74-5; Sequence=VSP_023192;
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues, including the
CC       liver and placenta, as well as in peripheral blood leukocytes.
CC       {ECO:0000269|PubMed:17991829}.
CC   -!- INDUCTION: Up-regulated by bacterial lipopolysaccharide (LPS) in
CC       bone marrow-derived macrophages. {ECO:0000269|PubMed:22245969}.
CC   -!- PTM: Phosphorylation at Ser-177 is required for deubiquitinating
CC       activity. {ECO:0000269|PubMed:22245969}.
CC   -!- SIMILARITY: Belongs to the peptidase C85 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB14131.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAB15416.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK022612; BAB14131.1; ALT_INIT; mRNA.
DR   EMBL; AK026260; BAB15416.1; ALT_INIT; mRNA.
DR   EMBL; AK294590; BAG57778.1; -; mRNA.
DR   EMBL; AF207550; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471224; EAW50724.1; -; Genomic_DNA.
DR   EMBL; BC009917; AAH09917.1; -; mRNA.
DR   EMBL; BC028225; AAH28225.1; -; mRNA.
DR   EMBL; BC098440; AAH98440.1; -; mRNA.
DR   EMBL; AL137509; CAB70778.1; -; mRNA.
DR   CCDS; CCDS14313.1; -. [Q96G74-1]
DR   CCDS; CCDS48104.1; -. [Q96G74-5]
DR   CCDS; CCDS48105.1; -. [Q96G74-4]
DR   PIR; T46265; T46265.
DR   RefSeq; NP_001129629.1; NM_001136157.1. [Q96G74-5]
DR   RefSeq; NP_001129630.1; NM_001136158.1. [Q96G74-5]
DR   RefSeq; NP_001129631.1; NM_001136159.1. [Q96G74-4]
DR   RefSeq; NP_060072.1; NM_017602.3. [Q96G74-1]
DR   RefSeq; XP_006724600.1; XM_006724537.2. [Q96G74-1]
DR   UniGene; Hs.496098; -.
DR   PDB; 3PFY; X-ray; 1.70 A; A=172-344.
DR   PDB; 3TMO; X-ray; 2.20 A; A=172-351.
DR   PDB; 3TMP; X-ray; 1.91 A; A/C/E/G=172-351.
DR   PDBsum; 3PFY; -.
DR   PDBsum; 3TMO; -.
DR   PDBsum; 3TMP; -.
DR   ProteinModelPortal; Q96G74; -.
DR   SMR; Q96G74; -.
DR   BioGrid; 120738; 22.
DR   DIP; DIP-53541N; -.
DR   IntAct; Q96G74; 16.
DR   MINT; MINT-1408843; -.
DR   STRING; 9606.ENSP00000156084; -.
DR   MEROPS; C85.001; -.
DR   iPTMnet; Q96G74; -.
DR   PhosphoSitePlus; Q96G74; -.
DR   BioMuta; OTUD5; -.
DR   DMDM; 74731791; -.
DR   EPD; Q96G74; -.
DR   MaxQB; Q96G74; -.
DR   PaxDb; Q96G74; -.
DR   PeptideAtlas; Q96G74; -.
DR   PRIDE; Q96G74; -.
DR   TopDownProteomics; Q96G74-2; -. [Q96G74-2]
DR   Ensembl; ENST00000156084; ENSP00000156084; ENSG00000068308. [Q96G74-1]
DR   Ensembl; ENST00000376488; ENSP00000365671; ENSG00000068308. [Q96G74-5]
DR   Ensembl; ENST00000396743; ENSP00000379969; ENSG00000068308. [Q96G74-5]
DR   Ensembl; ENST00000428668; ENSP00000401629; ENSG00000068308. [Q96G74-4]
DR   GeneID; 55593; -.
DR   KEGG; hsa:55593; -.
DR   UCSC; uc004dlt.5; human. [Q96G74-1]
DR   CTD; 55593; -.
DR   GeneCards; OTUD5; -.
DR   HGNC; HGNC:25402; OTUD5.
DR   HPA; HPA017375; -.
DR   MIM; 300713; gene.
DR   neXtProt; NX_Q96G74; -.
DR   OpenTargets; ENSG00000068308; -.
DR   PharmGKB; PA142671217; -.
DR   eggNOG; KOG2605; Eukaryota.
DR   eggNOG; ENOG410XNYW; LUCA.
DR   GeneTree; ENSGT00530000063508; -.
DR   HOGENOM; HOG000231360; -.
DR   HOVERGEN; HBG060214; -.
DR   InParanoid; Q96G74; -.
DR   KO; K12655; -.
DR   OMA; NKMHRDP; -.
DR   OrthoDB; EOG091G0NE6; -.
DR   PhylomeDB; Q96G74; -.
DR   TreeFam; TF326812; -.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-936440; Negative regulators of RIG-I/MDA5 signaling.
DR   ChiTaRS; OTUD5; human.
DR   GenomeRNAi; 55593; -.
DR   PRO; PR:Q96G74; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000068308; -.
DR   CleanEx; HS_OTUD5; -.
DR   ExpressionAtlas; Q96G74; baseline and differential.
DR   Genevisible; Q96G74; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:1990380; F:Lys48-specific deubiquitinase activity; IDA:MGI.
DR   GO; GO:0061578; F:Lys63-specific deubiquitinase activity; IDA:MGI.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:UniProtKB.
DR   GO; GO:0101005; F:ubiquitinyl hydrolase activity; IDA:MGI.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:MGI.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0070536; P:protein K63-linked deubiquitination; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:UniProtKB.
DR   InterPro; IPR031084; OTU5/OTLD1.
DR   InterPro; IPR003323; OTU_dom.
DR   PANTHER; PTHR12419:SF28; PTHR12419:SF28; 1.
DR   Pfam; PF02338; OTU; 1.
DR   PROSITE; PS50802; OTU; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Hydrolase;
KW   Phosphoprotein; Protease; Reference proteome; Thiol protease;
KW   Ubl conjugation pathway.
FT   CHAIN         1    571       OTU domain-containing protein 5.
FT                                /FTId=PRO_0000278223.
FT   DOMAIN      213    341       OTU. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00139}.
FT   REGION      218    224       Cys-loop. {ECO:0000250}.
FT   REGION      273    283       Variable-loop. {ECO:0000250}.
FT   REGION      329    334       His-loop. {ECO:0000250}.
FT   COMPBIAS      5    113       Pro-rich.
FT   COMPBIAS     33    174       Gly-rich.
FT   ACT_SITE    221    221       {ECO:0000255}.
FT   ACT_SITE    224    224       Nucleophile.
FT                                {ECO:0000269|PubMed:22245969}.
FT   ACT_SITE    334    334       {ECO:0000305|PubMed:22245969}.
FT   MOD_RES      64     64       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:22245969}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:22245969}.
FT   MOD_RES     175    175       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:22245969}.
FT   MOD_RES     177    177       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:22245969}.
FT   MOD_RES     452    452       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     507    507       Phosphothreonine.
FT                                {ECO:0000269|PubMed:22245969}.
FT   VAR_SEQ       1    217       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045185.
FT   VAR_SEQ      17     40       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_023195.
FT   VAR_SEQ     304    308       Missing (in isoform 2, isoform 3, isoform
FT                                4 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_023192.
FT   VAR_SEQ     563    566       HRDP -> PCRC (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_023193.
FT   VAR_SEQ     567    571       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_023194.
FT   MUTAGEN     177    177       S->D,E: Loss of deubiquitinase activity.
FT                                Abolishes activation by protein kinases.
FT                                {ECO:0000269|PubMed:22245969}.
FT   MUTAGEN     224    224       C->S: Loss of deubiquitinase activity.
FT                                Loss of suppression of IFN production.
FT                                {ECO:0000269|PubMed:17991829,
FT                                ECO:0000269|PubMed:22245969}.
FT   MUTAGEN     542    542       L->A: Loss of 'K-48'- and 'K-63'-linked
FT                                polyubiquitin chain binding. Partial loss
FT                                of TRAF3 deubiquitination; when
FT                                associated with A-549.
FT                                {ECO:0000269|PubMed:17991829}.
FT   MUTAGEN     549    549       S->A: Loss of 'K-48'- and 'K-63'-linked
FT                                polyubiquitin chain binding. Partial loss
FT                                of TRAF3 deubiquitination; when
FT                                associated with A-542.
FT                                {ECO:0000269|PubMed:17991829}.
FT   HELIX       178    180       {ECO:0000244|PDB:3TMP}.
FT   HELIX       181    186       {ECO:0000244|PDB:3TMP}.
FT   HELIX       193    211       {ECO:0000244|PDB:3PFY}.
FT   STRAND      214    216       {ECO:0000244|PDB:3PFY}.
FT   HELIX       224    234       {ECO:0000244|PDB:3PFY}.
FT   HELIX       237    239       {ECO:0000244|PDB:3PFY}.
FT   HELIX       240    253       {ECO:0000244|PDB:3PFY}.
FT   HELIX       255    258       {ECO:0000244|PDB:3PFY}.
FT   HELIX       259    261       {ECO:0000244|PDB:3TMP}.
FT   HELIX       266    273       {ECO:0000244|PDB:3TMP}.
FT   HELIX       282    292       {ECO:0000244|PDB:3PFY}.
FT   STRAND      296    301       {ECO:0000244|PDB:3PFY}.
FT   STRAND      303    305       {ECO:0000244|PDB:3TMO}.
FT   STRAND      311    314       {ECO:0000244|PDB:3PFY}.
FT   STRAND      325    330       {ECO:0000244|PDB:3PFY}.
FT   TURN        331    333       {ECO:0000244|PDB:3PFY}.
FT   STRAND      334    339       {ECO:0000244|PDB:3PFY}.
SQ   SEQUENCE   571 AA;  60626 MW;  F4B2B385B84ABC46 CRC64;
     MTILPKKKPP PPDADPANEP PPPGPMPPAP RRGGGVGVGG GGTGVGGGDR DRDSGVVGAR
     PRASPPPQGP LPGPPGALHR WALAVPPGAV AGPRPQQASP PPCGGPGGPG GGPGDALGAA
     AAGVGAAGVV VGVGGAVGVG GCCSGPGHSK RRRQAPGVGA VGGGSPEREE VGAGYNSEDE
     YEAAAARIEA MDPATVEQQE HWFEKALRDK KGFIIKQMKE DGACLFRAVA DQVYGDQDMH
     EVVRKHCMDY LMKNADYFSN YVTEDFTTYI NRKRKNNCHG NHIEMQAMAE MYNRPVEVYQ
     YSTGTSAVEP INTFHGIHQN EDEPIRVSYH RNIHYNSVVN PNKATIGVGL GLPSFKPGFA
     EQSLMKNAIK TSEESWIEQQ MLEDKKRATD WEATNEAIEE QVARESYLQW LRDQEKQARQ
     VRGPSQPRKA SATCSSATAA ASSGLEEWTS RSPRQRSSAS SPEHPELHAE LGMKPPSPGT
     VLALAKPPSP CAPGTSSQFS AGADRATSPL VSLYPALECR ALIQQMSPSA FGLNDWDDDE
     ILASVLAVSQ QEYLDSMKKN KVHRDPPPDK S
//
